Detail akcie Utd Therapeut online

Business Summary: United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, United Therapeutics Corp revenues increased 24% to $2.88B. Net income increased 21% to $1.2B. Revenues reflect Tyvaso DPI segment increase of 41% to $1.03B, Nebulized Tyvaso segment increase of 17% to $586.8M, United States segment increase of 24% to $2.74B, Rest of World segment increase of 10% to $137.7M. Net income was partially offset by Share-based compensation increase from $21.1M to $109.5M (expense).